Cerebrospinal Fluid Oxaliplatin Contributes to the Acute Pain Induced by Systemic Administration of Oxaliplatin
Authors:
- Zhen-Zhen HuangZHZhen-Zhen Huang
- Dai LiDLDai Li
- Han-Dong Ou-YangHOHan-Dong Ou-Yang
- Cui-Cui LiuCLCui-Cui Liu
- Xian-Guo LiuXLXian-Guo Liu
- Chao MaCMChao Ma
- Jia-You WeiJWJia-You Wei
- Yong LiuYLYong Liu
- Wen-Jun XinWXWen-Jun Xin
Open Access
- 1 May 2016
- journal article
- pain medicine
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 124 (5) , 1109-1121
Abstract
The administration of oxaliplatin to rats leads to nociceptive sensitization and the accumulation of the drug in cerebrospinal fluid. Oxaliplatin may support sensitization of spinal cord neurons through an epigenetic mechanism resulting in the up-regulation of CX3CL1. Background: Systemic administration of oxaliplatin has no effect on the tumors in the central nervous system (CNS) due to the limited concentration of oxaliplatin in the cerebrospinal fluid (CSF), while it was clinically reported that oxaliplatin can induce acute encephalopathy. Currently, the impairment of neuronal functions in the CNS after systemic administration of oxaliplatin remains uninvestigated. Methods: The von Frey test and the plantar test were performed to evaluate neuropathic pain behavior after a single intraperitoneal administration of oxaliplatin (4 mg/kg) in rats. Inductively coupled plasma–mass spectrometry, electrophysiologic recording, real-time quantitative reverse transcription polymerase chain reaction, chromatin immunoprecipitation, Western blot, immunohistochemistry, and small interfering RNA were applied to understand the mechanisms. Results: Concentration of oxaliplatin in CSF showed a time-dependent increase after a single administration of oxaliplatin. Spinal application of oxaliplatin at the detected concentration (6.6 nM) significantly increased the field potentials in the dorsal horn, induced acute mechanical allodynia (n = 12 each) and thermal hyperalgesia (n = 12 each), and enhanced the evoked excitatory postsynaptic currents and spontaneous excitatory postsynaptic currents in the projection neurokinin 1 receptor–expressing lamina I to II neurons. The authors further found that oxaliplatin significantly increased the nuclear factor-κB p65 binding and histone H4 acetylation in cx3cl1 promoter region. Thus, the upregulated spinal CX3CL1 markedly mediated the induction of central sensitization and acute pain behavior after oxaliplatin administration. Conclusions: The findings of this study suggested that oxaliplatin in CSF may directly impair the normal function of central neurons and contribute to the rapid development of CNS-related side effects during chemotherapy. This provides novel targets to prevent oxaliplatin-induced acute painful neuropathy and encephalopathy.Keywords
This publication has 46 references indexed in Scilit:
- Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)Journal of Clinical Oncology, 2015
- Chemotherapy-induced neuropathy: A comprehensive surveyCancer Treatment Reviews, 2014
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)Frontiers in Pharmacology, 2013
- Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature reviewAsia-Pacific Journal of Clinical Oncology, 2012
- Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primatesCancer Chemotherapy and Pharmacology, 2009
- Comparison of Oxaliplatin- and Cisplatin-Induced Painful Peripheral Neuropathy in the RatThe Journal of Pain, 2009
- Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman PrimatesClinical Cancer Research, 2005
- The taxanes: toxicity and quality of life considerations in advanced ovarian cancerBritish Journal of Cancer, 2003
- Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography–mass spectrometryJournal of Chromatography B, 2003